Overview
International law firm McDermott Will & Emery represented Spine Biopharma, Inc, a biopharmaceutical company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease, in the completion of its $13 million Series B equity financing. The company intends to use the financing to support further development of SB-01 For Injection (SB-01) also known as Remedisc™, a first-in-class therapeutic for the treatment of degenerative disc disease.
- The transaction was closed on March 17, 2022.
- The McDermott team was led by Merrill Kraines and Todd Kornfeld.
- Read Spine Biopharma’s press release here.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
